University of Kentucky at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

University of Kentucky takes part in 4 sessions at CTAD 2026 in Boston. Its program centres on non-amyloid targets, including hippocampal sclerosis of ageing and brain haemorrhage. Its work covers a nicorandil trial, a sensory-based dementia care trial and a review of real-world lecanemab use.

Organization	CTAD 2026 Attendance
University of Kentucky Lexington, Kentucky
uky.edu Universities & institutes Its Sanders-Brown Center on Aging runs an Alzheimer's Disease Research Center and studies hippocampal sclerosis and vascular dementia.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Safety and Modulation of ABCC9 pathways by nicorandil for the Treatment of Hippocampal Sclerosis of aging: The SMArT–HS Study primary outcome results (P050) Other mechanisms and targets Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH): Update on progress in a phase 2a proof-of-concept trial of a novel anti-neuroinflammatory small molecule drug candidate (P068) Other mechanisms and targets Poster Thu Nov 19 7:15am–5:00pm Design considerations of a phase II multi-site randomized controlled trial of Harmony Dementia Care: a sensory-based intervention for people with Alzheimer’s disease and related dementias (P388) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Real-World Effectiveness, Safety, and Patient Experience of Lecanemab in the United States: A Systematic Literature Review (P407) Anti-amyloid and anti-tau therapies · Real-world data and access

Organization

CTAD 2026 Attendance

University of Kentucky

Lexington, Kentucky

uky.edu

Universities & institutes

Its Sanders-Brown Center on Aging runs an Alzheimer's Disease Research Center and studies hippocampal sclerosis and vascular dementia.

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Safety and Modulation of ABCC9 pathways by nicorandil for the Treatment of Hippocampal Sclerosis of aging: The SMArT–HS Study primary outcome results (P050)

Other mechanisms and targets

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH): Update on progress in a phase 2a proof-of-concept trial of a novel anti-neuroinflammatory small molecule drug candidate (P068)

Other mechanisms and targets

Poster

Thu Nov 19
7:15am–5:00pm

Design considerations of a phase II multi-site randomized controlled trial of Harmony Dementia Care: a sensory-based intervention for people with Alzheimer’s disease and related dementias (P388)

Trial design and endpoints

Poster

Thu Nov 19
7:15am–5:00pm

Real-World Effectiveness, Safety, and Patient Experience of Lecanemab in the United States: A Systematic Literature Review (P407)

Anti-amyloid and anti-tau therapies · Real-world data and access

Instantly find 20 buyers from University of Kentucky

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction